《美股業績》強生(JNJ.US)首季經調整盈利勝預期 升今年銷售預測
強生(JNJ.US)公布,今年首季銷售額為247.5億美元(下同),按年增5.6%,優於預期;受嬰兒爽身粉負債及即將分拆消費者健康業務相關成本影響,強生首季盈轉虧蝕6,800萬元,去年同期賺51.5億元。每股稀釋後虧損0.03元。
按非通用會計準則(Non-GAAP),首季經調整盈利為70.7億元,按年跌0.9%,稀釋後每股盈利則增0.4%至2.68元,勝市場預期。
由於消費者健康、製藥和醫療設備三項業務錄強勁增長,強生上調今年業績指引,預期今年銷售額979億美元至989億美元,較1月份的預測高出約10億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.